(19)
(11) EP 3 144 014 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
26.04.2017 Bulletin 2017/17

(43) Date of publication:
22.03.2017 Bulletin 2017/12

(21) Application number: 15306469.6

(22) Date of filing: 21.09.2015
(51) International Patent Classification (IPC): 
A61K 45/06(2006.01)
A61K 31/4375(2006.01)
A61P 35/00(2006.01)
 A61K 31/437(2006.01)
A61K 31/5377(2006.01)
A61P 35/04(2006.01)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA

(71) Applicants:
  • COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES
    75015 Paris (FR)
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    75013 Paris (FR)

(72) Inventors:
  • GIACOSA, Sofia
    38110 LA TOUR DU PIN (FR)
  • PILLET, Catherine
    38450 VIF (FR)
  • COCHET, Claude
    38640 CLAIX (FR)
  • FILHOL-COCHET, Odile
    38640 CLAIX (FR)
  • BARETTE, Caroline
    38360 SASSENAGE (FR)
  • SOLEILHAC, Emmanuelle
    38960 SAINT ETIENNE DE CROSSEY (FR)

(74) Representative: Gevers & Orès 
41 avenue de Friedland
75008 Paris
75008 Paris (FR)

   


(54) A SYNTHETIC LETHAL DRUG COMBINATION FOR TREATING RENAL CELL CARCINOMA


(57) The present invention pertains to a novel treatment of renal cell carcinoma and other a solid tumors which harbor a VHL inactivation, based on the combination of a first agent inhibiting a protein kinase CK2 (CK2) and a second agent inhibiting an Ataxia Telangiectasia Mutated (ATM) kinase.